Relmada Therapeutics Inc (RLMD) - Net Assets
Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has net assets worth $86.51 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($94.00 Million) and total liabilities ($7.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Relmada Therapeutics Inc (RLMD) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $86.51 Million |
| % of Total Assets | 92.03% |
| Annual Growth Rate | 98.89% |
| 5-Year Change | -58.46% |
| 10-Year Change | 1128.45% |
| Growth Volatility | 2825.96 |
Relmada Therapeutics Inc - Net Assets Trend (2012–2025)
This chart illustrates how Relmada Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Relmada Therapeutics Inc (RLMD) total assets for the complete picture of this company's asset base.
Annual Net Assets for Relmada Therapeutics Inc (2012–2025)
The table below shows the annual net assets of Relmada Therapeutics Inc from 2012 to 2025. For live valuation and market cap data, see Relmada Therapeutics Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $86.51 Million | +143.55% |
| 2024-12-31 | $35.52 Million | -58.38% |
| 2023-12-31 | $85.36 Million | -39.22% |
| 2022-12-31 | $140.44 Million | -32.57% |
| 2021-12-31 | $208.26 Million | +97.25% |
| 2020-12-31 | $105.58 Million | -8.73% |
| 2019-12-31 | $115.68 Million | +2198.25% |
| 2018-12-31 | $-5.51 Million | -477.53% |
| 2017-12-31 | $1.46 Million | -79.26% |
| 2016-12-31 | $7.04 Million | -20.06% |
| 2015-12-31 | $8.81 Million | 0.00% |
| 2014-12-31 | $8.81 Million | +894.43% |
| 2014-06-30 | $-1.11 Million | 0.00% |
| 2013-12-31 | $-1.11 Million | -9863.70% |
| 2012-12-31 | $11.36K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Relmada Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 69825505600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $73.33K | 0.08% |
| Other Components | $784.71 Million | 907.05% |
| Total Equity | $86.51 Million | 100.00% |
Relmada Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Relmada Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kvutzat Acro Ltd.
TA:ACRO
|
$798.22 Million |
|
G-Shank Enterprise Co Ltd
TW:2476
|
$798.50 Million |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
$798.52 Million |
|
Goldcard High-Tech Co Ltd
SHE:300349
|
$798.55 Million |
|
Huawen Media Investment Corp
SHE:000793
|
$797.87 Million |
|
Evergreen International Storage & Transport Corp
TW:2607
|
$797.65 Million |
|
YD More Investments Ltd
TA:MRIN
|
$797.52 Million |
|
Nanjing Doron Technology Corp
SHG:603528
|
$797.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Relmada Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 35,521,961 to 86,512,013, a change of 50,990,052 (143.5%).
- Net loss of 57,385,163 reduced equity.
- New share issuances of 93,637,829 increased equity.
- Other factors increased equity by 14,737,386.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-57.39 Million | -66.33% |
| Share Issuances | $93.64 Million | +108.24% |
| Other Changes | $14.74 Million | +17.04% |
| Total Change | $- | 143.55% |
Book Value vs Market Value Analysis
This analysis compares Relmada Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2118.28x to 3.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.00 | $7.64 | x |
| 2013-12-31 | $-2.27 | $7.64 | x |
| 2014-06-30 | $-0.92 | $7.64 | x |
| 2014-12-31 | $3.54 | $7.64 | x |
| 2015-12-31 | $3.55 | $7.64 | x |
| 2016-12-31 | $2.43 | $7.64 | x |
| 2017-12-31 | $0.48 | $7.64 | x |
| 2018-12-31 | $-1.76 | $7.64 | x |
| 2019-12-31 | $12.53 | $7.64 | x |
| 2020-12-31 | $6.77 | $7.64 | x |
| 2021-12-31 | $11.87 | $7.64 | x |
| 2022-12-31 | $4.74 | $7.64 | x |
| 2023-12-31 | $2.84 | $7.64 | x |
| 2024-12-31 | $1.18 | $7.64 | x |
| 2025-12-31 | $2.19 | $7.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Relmada Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-66.33%) is above the historical average (-121.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -106.11% | -151.77% | 0.43x | 1.62x | $-13.19K |
| 2013 | 0.00% | -877.66% | 0.00x | 0.00x | $5.48 Million |
| 2014 | -236.14% | 0.00% | 0.00x | 2.77x | $-21.68 Million |
| 2015 | -236.14% | 0.00% | 0.00x | 2.77x | $-21.68 Million |
| 2016 | -42.24% | 0.00% | 0.00x | 1.45x | $-3.68 Million |
| 2017 | -430.53% | 0.00% | 0.00x | 1.94x | $-6.43 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.41 Million |
| 2019 | -12.97% | 0.00% | 0.00x | 1.01x | $-26.57 Million |
| 2020 | -56.31% | 0.00% | 0.00x | 1.12x | $-70.01 Million |
| 2021 | -60.38% | 0.00% | 0.00x | 1.07x | $-146.58 Million |
| 2022 | -111.83% | 0.00% | 0.00x | 1.09x | $-171.09 Million |
| 2023 | -115.74% | 0.00% | 0.00x | 1.14x | $-107.33 Million |
| 2024 | -225.15% | 0.00% | 0.00x | 1.29x | $-83.53 Million |
| 2025 | -66.33% | 0.00% | 0.00x | 1.09x | $-66.04 Million |
Industry Comparison
This section compares Relmada Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Relmada Therapeutics Inc (RLMD) | $86.51 Million | -106.11% | 0.09x | $798.21 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more